Blueprint Bio nearly raised $100m as biosecurity community debates slow returns on biotech

tyler_m_john · x · 2026-09-06

In a debate over biosecurity strategy, davidmanheim argues technical interventions like Blueprint Bio show real progress but have long RoI horizons — the fund backed David Baker's work in 2018, much of which is still in early-stage clinical trials. tylermjohn says he loves Blueprint Bio and nearly helped it raise $100m last year, adding that no one expected AI to move this fast, strengthening his case for top operators and doing everything faster.

Original post →

More from AGI Musings

AGI Musings channel →